BioPharma Dive February 13, 2025
Henry Gosebruch, Neumora’s CEO since 2023, will be succeeded by board chair Paul Berns. Elsewhere, Biogen discontinued four central nervous system programs.
Today, a brief rundown of news involving Neumora Therapeutics and Pliant Therapeutics, as well as updates from Biogen, AbbVie and SpringWorks Therapeutics that you might have missed.
Neumora Therapeutics CEO Henry Gosebruch is leaving the brain drug developer in a reshuffling of its executive ranks that will involve board chair and company co-founder Paul Berns becoming chief executive. In addition, Chief Financial Officer Joshua Pinto will become president; Chief Strategy Officer Bill Aurora will serve as chief operating and development officer; while Michael Milligan, currently a finance and accounting executive, will be promoted to CFO. Neumora expects readouts...
Today's Sponsors
Today's Sponsor